Conference call today at 4:30 PM ET may provide additional details. Monitor for analyst upgrades and potential partnership interest. Data readouts in H1 2027 are next catalyst.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $9.90entry
- T+1 · 7mo ago −6.41%α −6.40% · $9.27
- T+5 · 7mo ago +2.42%α +0.73% · $10.14
- T+20 · 6mo ago +16.16%α +10.69% · $11.50
- T+60 · 4mo ago +95.35%α +91.36% · $19.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca reported highly positive preliminary Phase 1 data for pan-RAS inhibitor ERAS-0015, showing 62% uORR in 2L+ KRAS G12X NSCLC (vs 38% for comparator RMC-6236) and 40% uORR in 2L PDAC (vs 29% comparator), with favorable safety. This is a major catalyst for the stock, potentially positioning ERAS-0015 as best-in-class.
Key Facts
- 62% uORR in 2L+ KRAS G12X NSCLC at PAD 16-32 mg QD vs 38% comparator
- 75% uORR in post-ICI/platinum 2/3L NSCLC at PAD vs 38% comparator
- 40% uORR in 2L KRAS G12X PDAC at PAD vs 29% comparator
- No DLTs, low-grade AEs, no discontinuations due to TRAEs
- RDE selected as 24-32 mg QD; monotherapy expansion and combo cohorts initiated
- Anticipated data disclosure narrowed to H1 2027
Financial Impact
Significant valuation increase expected; ERAS-0015 could address large NSCLC and PDAC markets if approved
Risk Factors
- Data are preliminary and based on small sample sizes; unconfirmed responses
- Cross-trial comparison limitations with RMC-6236
- Regulatory and clinical development risks; need to confirm durability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281996 |
Track record
26 reports on ERAS
3 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers